 |
市場調查報告書
商品編碼
1983321
疼痛管理藥物市場：按藥物類別、通路和地區分類Pain Management Drugs Market, By Drug Class, By Distribution Channel, By Geography |
||||||
2026年，疼痛管理藥物市場規模估計為884億美元，預計2033年將達到1,131.5億美元。預計從2026年到2033年，該市場將以3.6%的複合年成長率成長。
| 分析範圍 | 分析詳情 | ||
|---|---|---|---|
| 基準年 | 2025 | 市場規模（2026 年） | 884億美元 |
| 效能數據 | 2020-2024 | 預測期 | 2026-2033 |
| 預測期（2026-2033 年）複合年成長率 | 3.60% | 預計金額（2033 年） | 1131.5億美元 |
鎮痛藥是一類透過作用於疼痛受體來緩解疼痛症狀的藥物。這些藥物包括鴉片類藥物、非類固醇消炎劑（NSAIDs）、抗驚厥藥、抗憂鬱症和肌肉鬆弛劑。這些藥物用於治療疼痛，其適應症列於附加檔中，部分藥物也用於仿單標示外。例如，抗驚厥藥和抗憂鬱症最初分別用於治療癲癇和憂鬱症。然而，這些藥物已被證實對緩解疼痛症狀有效，因此也被仿單標示外用於鎮痛。此外，鴉片類藥物主要用於治療急性和慢性疼痛。這導致患者自行用藥，造成鴉片類藥物製劑的濫用和過量。另外，許多藥物的專利保護期已過多年，其學名藥已廣泛上市。非處方止痛藥包括Fentanyl、氫嗎啡酮、羥考酮、阿斯匹靈和Diazepam。
市場動態
全球疼痛管理藥物市場受多種因素驅動，例如缺乏替代療法以及學名藥生產商的強大影響力。例如，根據美國國家生物技術資訊中心 (NCBI) 2018 年 2 月發布的數據，許多主要藥物，如奧施康定 (OxyContin)、奧帕納緩釋片 (Opana ER) 和Celebrex)的非專利保護期已過，非專利藥生產商開發出的產品種類，推動了疼痛管理藥物市場的成長繁多。在預測期內，持續的藥物需求和便捷的取得途徑預計將繼續推動鎮痛藥的使用。這些藥物在改善治療效果方面的顯著療效以及癌症（可導致癌症疼痛）等疾病盛行率的不斷上升，正在促進疼痛管理藥物市場的成長。然而，這些藥物可能存在危及生命的副作用（包裝上的黑框警告已對此進行了說明），以及主要企業研發投入的不足，預計將阻礙疼痛管理藥物市場的成長。
本報告的主要特點
- 本報告指出了各個細分市場的潛在商機，並描述了該市場中一系列有吸引力的投資提案。
- 此外，它還提供了有關市場促進因素和限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要企業採取的競爭策略的重要見解。
- 本節根據以下參數，介紹全球疼痛管理藥物市場中主要企業的概況：公司概況、產品系列、主要亮點、財務表現和策略。
- 本報告中的見解將使負責人和企業經營團隊能夠就未來的產品發布、產品線更新、市場擴張和行銷策略做出明智的決策。
- 《全球疼痛管理藥物市場》報告面向該行業的各種相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
- 相關人員可以透過分析全球疼痛管理藥物市場中使用的各種策略矩陣來促進決策。
目錄
第1章：分析目標與假設
- 分析目的
- 先決條件
- 簡稱
第2章 市場展望
- 報告說明
- 市場定義和範圍
- 執行摘要
第3章：市場動態、監管與趨勢分析
- 市場動態
- 影響分析
- 主要亮點
- 法規環境
- 產品上市及核准
- PEST分析
- 波特五力分析
- 市場機遇
- 法規環境
- 主要進展
- 產業趨勢
第4章：全球疼痛管理藥物市場：依藥物類別分類（2020-2033 年）
- 鴉片類藥物
- NSAIDs
- 抗驚厥藥物
- 抗憂鬱症
- 其他
第5章：全球疼痛管理藥物市場：依通路分類（2020-2033 年）
- 醫院藥房
- 零售藥房
- 網路藥房
第6章：全球疼痛管理藥物市場：按地區分類（2020-2033 年）
- 北美洲
- 美國
- 加拿大
- 拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲
- 歐洲
- 德國
- 英國
- 西班牙
- 法國
- 義大利
- 俄羅斯
- 其他歐洲國家
- 亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 亞太其他地區
- 中東
- 海灣合作理事會國家
- 以色列
- 其他中東國家
- 非洲
- 南非
- 北非
- 中非
第7章 競爭情勢
- Pfizer, Inc.
- Sanofi SA
- Mylan NV
- Teva Pharmaceutical Industries Ltd.
- Eily, Lilly, and Company
- Abbott Laboratories
- Purdue Pharma LP
- GlaxoSmithKline Plc
- Johnson &Johnson
- F. Hoffmann La Roche Ltd.
第8章 分析師建議
- 機會
- 分析師意見
- Coherent Opportunity Map (COM)
第9章 參考文獻與分析方法
- 參考
- 分析方法
- 關於 Coherent Market Insights
Pain Management Drugs Market is estimated to be valued at USD 88.4 Bn in 2026 and is expected to reach USD 113.15 Bn by 2033, growing at a compound annual growth rate (CAGR) of 3.6% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 88.4 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 3.60% | 2033 Value Projection: | USD 113.15 Bn |
Pain management medications are specific drug classes, which have pharmacological actions on pain receptors and work against the pain symptoms. These medications include opioids, non-steroidal anti-inflammatory drugs (NSAIDs), anticonvulsants, antidepressants, muscle relaxants, and others. These medications can be used for pain management of conditions, as indicated on label and some medications have off-label uses. For instance, anticonvulsants and antidepressants were originally used for the management of epilepsy and depression respectively. However, these medications have shown activity against pain indications and are prescribed for pain management as off-label indication. Moreover, opioids are majorly prescribed for the management of acute as well as chronic pain. This has also resulted in self-medication by patients, resulting in misuse or overdose of opioid containing drug products. Moreover, majority of the drugs have lost patent protection over the years and generic versions of the same are widely available in the market. Commercially available pain management drugs include Fentanyl, Hydromorphone, Oxycodone, Aspirin, Diazepam, and others.
Market Dynamics
The global pain management drugs market is driven by factors such as absence of alternative therapies and high presence of generic drug manufacturers in the market. For instance, in February 2018, according to data published by National Center for Biotechnology Information, increasing number of major drugs such as OxyContin, Opana ER, and Celebrex have lost patent protection due to which generic manufacturers have developed generic version with product variations fostering growth of the pain management drugs market. Continuous requirement of the medication coupled with easy availability is expected to boost the adoption of pain drugs over the forecast period. Proven effectiveness of these medications in improving medical outcomes and increasing prevalence of disorders such as cancer (leading to cancer pain) are fueling growth of the pain management drugs market. However, life threatening side effects associated with these medications, as indicated by the black box warning on the packaging, as well as lack of research and development by major players are expected to hinder growth of the pain management drugs market.
Key features of the study
- This report provides an in-depth analysis of the global pain management drugs market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global pain management drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Pfizer, Inc., Sanofi S.A., Mylan N.V., Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Abbott Laboratories, Purdue Pharma L.P., GlaxoSmithKline Plc, Johnson & Johnson, and F. Hoffmann La Roche Ltd.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global pain management drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global pain management drugs market
Market Segmentation
- Drug Class Insights (Revenue, USD Bn, 2026 - 2033)
- Opioids
- NSAIDs
- Anticonvulsants
- Antidepressants
- Others
- Distribution Channel Insights (Revenue, USD Bn, 2026 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Bn, 2026 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- North Africa
- Central Africa
- South Africa
- Key Players Insights
- Pfizer, Inc.
- Sanofi S.A.
- Mylan N.V.
- Teva Pharmaceutical Industries Ltd.
- Eily, Lilly, and Company
- Abbott Laboratories
- Purdue Pharma L.P.
- GlaxoSmithKline Plc
- Johnson & Johnson
- F. Hoffmann La Roche Ltd.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Pain Management Drugs Market, By Drug Class
- Global Pain Management Drugs Market, By Distribution Channel
- Global Pain Management Drugs Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Market Opportunities
- Regulatory Scenario
- Key Developments
- Industry Trend
4. Global Pain Management Drugs Market, By Drug Class, 2020-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Opioids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
- NSAIDs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
- Anticonvulsants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
- Antidepressants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
5. Global Pain Management Drugs Market, By Distribution Channel, 2020-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
6. Global Pain Management Drugs Market, By Region, 2020 - 2033, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2033, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
7. Competitive Landscape
- Pfizer, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi S.A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Mylan N.V.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eily, Lilly, and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Abbott Laboratories
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Purdue Pharma L.P.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GlaxoSmithKline Plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- F. Hoffmann La Roche Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
8. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
9. References and Research Methodology
- References
- Research Methodology
- About us
